Sign-up for our newsletter
MAIN
Event Calendar
Awardee Reports
ABOUT DIACOMP
Citing DiaComp
Contact
Committees
Institutions
Awardee Reports
Funding Programs
Pilot & Feasibility
Conference Support
Summer Student
Collaborative
External Funding Programs
Publications
Bioinformatics
RESOURCES
Protocols & Methods
Reagents & Resources
Mouse Diet
Breeding Schemes
Validation Criteria
IMPC / KOMP Data
Publications
Bioinformatics
FUNDING PROGRAMS
Pilot & Feasibility
Conference Support
Summer Student
Collaborative
External Funding Programs
CONTACT
PARTICIPANT AREA
Login
Request Account
▹
DiaComp Funded Abstracts
Program Application Abstract
Dyslipidemia increases CCL2 production via a mTORC1-FOXK1 pathway.
Jasper, Hsuan-Chieh
(University of Washington)
Mentor: Kanter, Jenny
Summer Student Program
Atherosclerosis is a chronic inflammatory disease in which macrophages perpetually infiltrate the artery walls. Macrophages are potent mediators of the inflammatory response in cardiovascular disease (CVD) and are also responsible for much of the physiological response to insult. Diabetes results in a 2- 10 fold increased risk of CVD, but the underlying mechanisms remain yet to be elucidated. Diabetes is commonly associated with diabetic dyslipidemia, which has a characteristic profile of elevated plasma triglycerides and triglyceride-rich lipoproteins. In this work, we investigate the involvement of the mTOR (mammalian target of rapamycin)-FOXK1 pathway and its role in lipid-induced elevation of Ccl2 (C-C chemokine ligand 2) expression. CCL2 is a chemokine heavily involved in macrophage recruitment. RT-PCR showed that thioglycolate-elicited macrophages which were stimulated with acetylated lowdensity lipoprotein (acLDL) showed a 2-fold increase in Ccl2 expression as compared to vehicle, an effect which was completely suppressed by inhibition of mTORC1 (mTOR Complex 1) by rapamycin treatment. Il1b expression was not upregulated in response to acLDL. Similarly, LPS-induced expression of Ccl2, but not Il1b, was sensitive to rapamycin. Recent research has also linked Forkhead box K1 (FOXK1), a downstream target of the mTORC1 pathway, to regulation of Ccl2 expression. Dyslipidemia activates the mTORC1 axis via phosphorylation, which in turn dephosphorylates FOXK1, resulting in upregulation of Ccl2 expression. Using BMDMs (bone marrow derived macrophages) treated with FOXK1 targeted siRNA, we were able to knockdown FOXK1 expression and investigate its effects on Ccl2 expression. Our findings implicate mTORC1-FOXK1 as a novel regulatory pathway of Ccl2 expression which can be activated by dyslipidemia. These findings establish a potential axis linking diabetes-induced dyslipidemia and chronic inflammation.
Welcome to the DiaComp Login / Account Request Page.
Email Address:
Password:
Note: Passwords are case-sensitive.
Please save my Email Address on this machine.
Not a member?
If you are a funded DiaComp investigator, a member of an investigator's lab,
or an external advisor to the consortium, please
request an account.
Forgot your password?
Enter your Email Address and
click here.
ERROR!
There was a problem with the page:
User Info
User Confirm
Safari Browser Detected...
We strive to make the DiaComp site compatable with as many browsers as possible, but some of our third party tools don't work with the Safari browser.
In order to explore this site we highly recommend using the most recent versions of the following browsers:
Internet Explorer
Google Chrome
FireFox
Please acknowledge all posters, manuscripts or scientific materials that were generated in part or whole using funds from the Diabetic Complications Consortium(DiaComp) using the following text:
Financial support for this work provided by the NIDDK Diabetic Complications Consortium (RRID:SCR_001415, www.diacomp.org), grants DK076169 and DK115255
Citation text and image have been copied to your clipboard. You may now paste them into your document. Thank you!